Deutsche Bank Upgrades Moderna to Hold, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Emmanuel Papadakis has upgraded Moderna (NASDAQ:MRNA) from Sell to Hold and lowered the price target from $85 to $80.
August 07, 2024 | 12:14 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Deutsche Bank has upgraded Moderna from Sell to Hold, while lowering the price target from $85 to $80.
The upgrade from Sell to Hold is a positive signal, indicating that the stock is no longer expected to underperform significantly. However, the lowered price target suggests limited upside potential in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100